helenalin has been researched along with Hepatocellular Carcinoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Duan, M; Fan, J; Gao, Q; Liu, LZ; Shi, JY; Song, FN; Wang, XY; Wang, ZC; Yang, LX; Zhou, J | 1 |
1 other study(ies) available for helenalin and Hepatocellular Carcinoma
Article | Year |
---|---|
RANKL promotes migration and invasion of hepatocellular carcinoma cells via NF-κB-mediated epithelial-mesenchymal transition.
Topics: Antigens, CD; Antineoplastic Agents, Phytogenic; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Collagenases; Diffusion Chambers, Culture; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Neoplasm Invasiveness; NF-kappa B; Nuclear Proteins; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Sesquiterpenes; Sesquiterpenes, Guaiane; Signal Transduction; Snail Family Transcription Factors; Transcription Factors; Twist-Related Protein 1; Vimentin | 2014 |